Apollo Hospitals
ICICI Direct
Broker Research reports: Buy reports
for all stocks
- This broker has downgraded this stock from it's previous report. (eg. - Buy->Hold)
- Broker has maintained previous recommendation but reduced share price target.
- This broker has upgraded this stock from it's previous report.(eg. - Sell->Hold)
- Broker has maintained previous recommendation but increased share price target.
RESEARCH REPORTS ALERTS
Load latest
Google or static link led you to an intermediate page.
- All Recent
- Upside
- Buy
- Sell
- Recent Upgrades
- Recent Downgrades
- IPO
- Sector Updates
- Most Recent
- Top Upside
Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.
| Summary | Date | Stock | Author | LTP | Target | Price at reco (Change since reco%) |
Upside(%) | Type | Report | Discuss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 31 May 2023 | Apollo Hospitals |
ICICI Direct
|
7806.50 | 5440.00 | 4621.95 (68.90%) | Target met |
Buy
|
||||
| 31 May 2023 | Torrent Pharma |
ICICI Direct
|
3629.20 | 2010.00 | 1835.80 (97.69%) | Target met |
Buy
|
||||
| 31 May 2023 | JK Cement |
ICICI Direct
|
6862.00 | 3780.00 | 3208.30 (113.88%) | Target met |
Buy
|
||||
| 31 May 2023 | ISGEC Heavy Engg |
ICICI Securities Limited
|
985.20 | 698.00 | 589.55 (67.11%) | Target met |
Buy
|
Good visibility on revenue amid margin improvement
ICICI Securities Limited
ISGEC Heavy Engineering’s (ISGEC) Q4FY23 standalone revenue increased 4% YoY to Rs14bn aided by EPC revenue growth of 8% YoY whereas manufacturing segment revenue declined 4% YoY. Improvement in the share of high-margin manufacturing business led to marginal improvement in EBIDTA margin by 247bps YoY to 7.4%.
|
|||
| 31 May 2023 | Vijaya Diagnostic Centre |
ICICI Securities Limited
|
1057.90 | 455.00 | 383.65 (175.75%) | Target met |
Buy
|
Non-covid patient footfall sturdy
ICICI Securities Limited
Vijaya Diagnostic Centre’s (Vijaya) Q4FY23 performance was driven by a steady 22.4% YoY growth in non-covid business, while covid business’ contribution fell to 1% (15% in Q4FY22). Overheads of new centres impacted EBITDA margin to a small extent though, at 40.6% in Q4, it continues to be better than that of most of listed peers.
|
|||
| 31 May 2023 | JK Cement |
ICICI Securities Limited
|
6862.00 | 3856.00 | 3177.70 (115.94%) | Target met |
Buy
|
Continues to impress
ICICI Securities Limited
JK Cement’s (JKCE) Q4FY23 performance was impressive on multiple counts: a) grey cement volumes surged 17% YoY (similar to FY23); b) grey cement realisations rose 1.6% QoQ (~3% QoQ for the standalone entity) defying the industry trend of a marginal decline.
|
|||
| 31 May 2023 | 3M |
ICICI Securities Limited
|
29915.00 | 29150.00 | 24817.45 (20.54%) | Target met |
Buy
|
Contract manufacturing & distribution agreement for Healthcare segment to be value accretive
ICICI Securities Limited
3M India reported 5th consecutive quarter of EBITDA growth higher than 23% YoY. Strong revival in manufacturing, infrastructure and automotive sectors has resulted in healthy growth for 3M India. Correction in crude oil prices, other commodities and stable forex rates also offer margin tailwinds.
|
|||
| 30 May 2023 | Ashok Leyland |
Geojit BNP Paribas
|
140.89 | 168.00 | 145.85 (-3.40%) | Target met |
Buy
|
||||
| 30 May 2023 | Bharat Electronics |
Geojit BNP Paribas
|
408.90 | 123.00 | 111.25 (267.55%) | Target met |
Buy
|
||||
| 30 May 2023 | NOCIL |
Sharekhan
|
181.20 | 260.00 | 225.80 (-19.75%) | Target met |
Buy
|
||||
|
more
loading
|
|||||||||||
* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.